Abstract
wildpixel / Getty Images
Hope for Stomach Cancer patients can now get no-cost cancer lab services thanks to an agreement struck recently with precision medicine company Perthera. Under the collaboration, patients will receive an evaluation via Perthera’s Precision Cancer Analysis (PCA) service, which brings together a variety of CLIA/CAP accredited labs to perform genomic and proteomic tissue analysis, in cooperation with a patient’s care team.
“We’re hopeful that through this new program stomach cancer patients can get a PCA so they can be treated with precision drugs more often,” said Aki Smith, founder of Hope for Stomach Cancer.
Once a partner lab returns its genomic and proteomic results to Perthera, the company applies its proprietary data tool and analysis by internal cancer specialists to produce a report offering clinical recommendations for a precision approach to treating each patient’s cancer.
“Hope for Stomach Cancer’s program is another sign that precision medicine is morphing from its emerging technology stage into a very real and powerful cancer treatment component,” said Andrew Mignatti, CEO and president of Perthera.